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Summary
Objectives: Examine factors associated with opioid adverse drug events
(ADE) in children.
Specific Aims: Examine whether adjuvant nonopioid use is associated with a
decreased probability of opioid-ADEs and need for rescue.
Background: Opioid-ADEs contribute to serious preventable harm for
hospitalized children. Adjuvant nonopioid use may mitigate opioid risk
postoperatively, yet few studies support this notion.
Method: This nested case–control study included children who required
intervention or rescue from opioid-ADEs and procedure-matched controls.
Data were recorded from medical records and primary outcomes included
serious opioid-ADEs (over-sedation and respiratory depression) and need
for rescue (e.g., naloxone, rapid response team). Hierarchical logistic
regression (HLR) models examined relationships between factors and opi-
oid-ADEs. Early clinical signs and symptoms of deterioration were exam-
ined.
Results: Twenty five children with opioid-ADEs and 98 children without
events were included. ASA-PS remained an independent risk factor (odds
ratio, 2.56 [1.09, 6.03]; P = 0.031), while adjuvant nonopioids a risk reduction
factor for opioid-ADEs (OR, 0.16 [0.05, 0.47]; P = 0.001) and need for rescue
(0.14 [0.04, 0.47]; P = 0.001). Supplemental oxygen use at PACU discharge
was associated with an increased odds of opioid-ADEs (OR, 3.72 [1.35,
10.23]; P = 0.007) and need for rescue (5.5 [1.7, 17.82]; P = 0.002).
Conclusions: Findings from this study suggest that strategies such as early
use of adjuvant nonopioids may reduce risk of opioid-ADEs postoperatively.
Furthermore, children who require supplemental oxygen early postopera-
tively may be at heightened risk of later events.
Introduction
Opioids are a primary source of adverse drug events
(ADE) (1–3) contributing to serious preventable harm
for hospitalized children (4). These agents have been
associated with 20–51% of drug events and errors (2,3).
Associated morbidity, mortality, and resource utiliza-
tion suggest an urgent need to decrease the occurrence
of opioid-ADEs (1,2,5).
The risk of opioid-ADEs may be higher early postopera-
tively and among children, given their variable response to
medications (5). These risks were underscored by findings
that 24% of children experienced a potentially serious
postoperative opioid-ADE warranting intervention, rescue,
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or escalation of care (6). Such reports motivated calls for
risk reduction strategies that include, enhanced risk stratifi-
cation, monitoring, and assessment to ensure early detec-
tion and intervention (7–9) and consideration of opioid-
sparing techniques, such as adjuvant use of nonopioids (8).
The insufficiency of risk stratification, to date, has led to an
emphasis on comprehensive surveillance for early detection
of deterioration (9,10). Yet, ongoing adverse events and
mortality in settings with continuous physiologic monitor-
ing (11) suggest an influence of other factors, such as inat-
tention or inadequate early intervention. It is therefore
suggested that more emphasis be placed on strategies such
as nonopioid use that may reduce opioid consumption
(12); however, little is known about the impact of such
strategies on safety. Such data are needed to bolster strate-
gies that promote safety in vulnerable groups.
This nested case–control study examined the relation-
ship between patient factors, treatment factors, and opi-
oid outcomes in hospitalized children during the early
postoperative period. It was hypothesized that early
adjuvant use of nonopioids would reduce the risk of
serious opioid-ADEs and need for rescue postopera-
tively. A secondary aim was to identify early clinical
warning signs for opioid-ADEs and need for rescue.
Materials and methods
A partial analysis of data from an ongoing study of
adverse postoperative events1 identified using rapid
response team (RRT) records was conducted. With IRB
approval and waiver of consent, the RRT, cardiopulmo-
nary arrest, and pharmacy naloxone patient lists were
reviewed to identify children who experienced rescue
events on general care units within 1 week postopera-
tively. Controls were selected from the fixed base popu-
lation of children receiving anesthetics over the same
study period (January 2009–March 2011). Two controls
were procedure-matched to every rescue case with the
first selected at random from the procedure subgroup
and the second using sequential numbering. Excluded
were patients who were aged > 20 years, had an outpa-
tient or cardiothoracic procedure, underlying hematol-
ogy/oncology condition or receiving opioids within
1 week preoperatively (i.e., potentially opioid tolerant),
a nonopioid-related rescue event or an event in the
intensive care unit (ICU), or never received opioids.
Trained assistants reviewed all records (i.e., automatic-
capture electronic perioperative records, the electronic
progress notes, medication order and administration
data, and nursing flow-sheets) and recorded the following
data: demographics and medical history, American Soci-
ety of Anesthesiologists Physical Status (ASA-PS), proce-
dure data, recovery progress over the first 48 h (vital
signs [VS], oxygen saturation [SpO2], fraction of inspired
oxygen [FiO2], pain [0–10 self-report numeric rating or
FLACC behavioral scale] and sedation scores [University
of Michigan Sedation Scale-UMSS, 0–4, where 4 =
unarousable] (13)), analgesics, and event details. To
improve the reliable identification of opioid-ADEs, a
structured trigger tool was modified from the Pediatric
Trigger Toolkit Guide to Identifying ADEs in Children’s
Hospital Settings (2,5) to include descriptors of interven-
tions [e.g., naloxone, supplemental oxygen (O2)] and
events (e.g., oxygen desaturation) potentially indicative of
opioid- or sedative-related ADEs. Oxygen desatura-
tion was defined as SpO2<92%, and oversedation as
UMSS  2 (i.e., moderate to deep sedation) accompa-
nied by a progress note identifying excessive sleepiness
warranting an intervention. Respiratory depression was
defined as respiratory rate  16 for infants < 6 months
of age,  12 for 6 m-2 years,  10 for 3–10 years, and
 8 for > 10 years. Type and amount of analgesics (opi-
oid and nonopioid) administered were recorded from the
electronic medication administration record for every 8-h
period on postoperative day 1 and for the 24-h period on
day 2. Nonopioids included acetaminophen, ibuprofen,
and ketorolac. For children with potential opioid-ADEs
as identified from the trigger tool, analgesics and VS were
recorded for 2 h increments preceding the event up to
12 h to establish temporal relationships to the event.
Length of stay and mortality were noted.
Definition of outcomes
A secondary review was conducted by the primary inves-
tigator for all subjects to ensure completeness and to code
opioid-ADEs based on a temporal relationship to opioids
and sedatives. The primary outcome was Opioid-ADE
that included children with potentially life-threatening
events. The secondary outcome was need for rescue
which included the subset of opioid-ADEs requiring nal-
oxone, airway management, or transfer to an ICU. Chil-
dren with these outcomes were compared with controls
(children with no events), and those with need for rescue
were further compared with children with threshold
events (i.e., the subset of those needing an intermediate
intervention such as O2, decrease or change in analgesic,
or increased assessment). To ensure reliability of coding,
event and medication data for all potential opioid-ADEs
1Aims of larger study include describing the nature and timing of
postoperative adverse events (PAE) in children; identify potential
warning signs in the PACU; describe nurse assessment and staffing
patterns associated with occurrence of PAE. All patients with RRT
or CPA events are included in the larger study. This paper is the
first manuscript from this study.
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and a random selection of nonopioid-ADE cases were
independently reviewed by two co-authors who coded the
nature of each event (threshold vs. rescue vs. nonevent).
Exact agreement occurred for all but two cases: one
where a 2-year-old had severe desaturation after low
doses of morphine and a benzodiazepine within 3 h of
postanesthesia care unit discharge (PACU DC), and the
other an infant with sleep apnea who had oxygen desatu-
ration 4 h after a low dose of an oral opioid, responding
to naloxone. These cases were considered potential
opioid-ADEs and included in the case group.
Statistical analysis
All data were analyzed using SPSS statistical software
(v.18, Chicago, IL, USA). Morphine equivalents
(mgkg1) were calculated using standard equianalgesic
conversions for intraoperative, PACU, and post-PACU
doses administered, and for initial opioid doses ordered.
Surgical severity was scored using a validated tool where
A = noninvasive (e.g., superficial peripheral), B = inva-
sive with moderate blood loss or airway procedure (e.g.,
incision and drainage, tonsillectomy), and C = signifi-
cantly invasive (e.g., spine fusion) (14) and inter-rater reli-
ability was excellent (a = 0.915). Data are described as;
n (%); means ± SD or 95% confidence intervals [CI], and
odds ratios [CI]. Chi square with Fisher’s exact tests com-
pared binominal data and unpaired t-tests with Levene’s
tests compared continuous data.
Hierarchical logistic regression (HLR) models with forced
entry of independent variables examined predictors for opi-
oid-ADE and need for rescue. Patient factors that were dif-
ferent between groups (P < 0.10; two-sided) were entered at
the first blocks, followed by the nonopioid factor at the final
block to determine the relative contribution of nonopioids
to the outcomes. The models were subsequently evaluated
for the ability to discriminate opioid-ADEs or need for res-
cue using receiver operating characteristic curves, with the
predicted probabilities as the test variable (15).
Extreme clinical signs (e.g., low SpO2) during PACU,
at PACU DC and during the first 8 h as well as opioid
consumption over time, were compared between groups
using Kruskal–Wallis one-way analysis of variance with
Friedman’s tests, because assumptions of normality
were not met (Kolmogorov-Smirnov statistics < 0.05).
P values < 0.05 (two-sided) were considered significant.
Sample size
As the derived sample was based on a fixed data set,
post hoc analysis revealed that a sample of 26 children per
group would have 80% power (P = 0.05) to detect what
Cohen describes as a large effect size (0.5) between children
with opioid-ADEs and those without these events (16).
Results
Figure 1 depicts the selection of cases. Sixteen of 86
patients with rescue events met inclusion criteria and had
experienced an opioid-ADE. The trigger tool identified
nine additional children with threshold events from the
case-matched selection. The resultant study group included
the 25 children with opioid-ADEs, and the control group
comprised 98 who received opioids without event.
Event description
Seventeen of the opioid-ADEs (68%) involved oxygen
desaturation, 13 (52%) over-sedation, 7 (28%) respiratory
depression, 5 (20%) agitation, and 1 (4%) hypotension.




No surgery = 174;
*Ineligible = 46
Not verifiable = 12
Cardiopulmonary Arrest




No surgery = 41;
Ineligible = 100;
Not verifiable = 8
Excluded 44
No surgery = 29; 
Ineligible = 15
Rescue Event Cases
N = 86 children (with 102 events)
1 event occurred in 73 
2 occurred in 10





Total Anesthe c Cases
N = 12,210
Opioid ADE (rescue)






Figure 1 Selection of study subjects.
aIneligible = cardiac surgery, event occurred
preoperatively, event because of nonclinical
reason (e.g., blood draw assistance),
patient > 20 years of age, hematologic/onco-
logic condition, no opioids received.
bPopulation of noncardiac, admissions after
surgery only,  20 years of age. cAdverse
drug event = Serious event associated or
potentially associated with drug administra-
tion.
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13 (52%) naloxone, and 13 (52%) a decrease in opioid
dose (the difference in preevent opioid use, however, was
not significantly different compared with 0–8, 8–16, or
16–24 h use; P = 0.238). Less common interventions
included 7 (28%) medication changes, 5 (20%) airway
management (i.e., three cases jaw thrust, one nasopharyn-
geal airway, one endotracheal intubation), and 5 (20%)
required escalation of care to a moderate care or ICU set-
ting. The time from PACU DC to an opioid-ADE was
17.85 h [4.5, 31.2], and the time to threshold vs rescue
events was not different (13.9 [5.03, 22.79] vs. 13.06 [1.00,
25.16] h, respectively, P = 0.65). The opioid-ADE group
had more nursing assessments per shift compared with
controls (4.1 [3.2, 5.0] vs. 3.3 [2.8, 3.8]; P < 0.001), but a
similar use of continuous pulse oximetry monitoring (88%
vs. 72%, P = 0.124). The hospital length of stay was
longer for children with opioid-ADE (8.7 [5.24, 12.12] vs.
controls 5.40 [2.36, 8.44]; P < 0.001), and there were no
deaths or permanent injury.
Aim 1: Association between nonopioids and
opioid-ADEs and need for rescue
Univariate comparisons found differences in ASA-PS,
musculoskeletal condition, use of IV-NCA, and continu-
ous opioid infusion, but not in perioperative or postoper-
ative opioid use during the first 48 h (Table 1). Overall
morphine equivalents during this timeframe were not sig-
nificantly different between children who received adju-
vant nonopioids and those who did not (0.005 [0.004,
0.007] vs. 0.008 [0.001, 0.012] mgkg1h1; P = 0.408);
however, the opioid-ADE group had lower odds of hav-
ing received adjuvant nonopioids. The HLRmodel coeffi-
cients confirmed the goodness of fit and supported the
hypothesis that early nonopioid use was associated with a
decreased probability of opioid-ADEs, and the c-statistic
supported the model’s prognostic ability (Table 2).
Compared with controls, the subgroup of children
who needed rescue was less likely to have had an ASA-
PS of 1 (0.78 [0.70, 0.86]; P = 0.039] and less likely to
have received adjuvant nonopioids (OR 0.21 [0.07,
0.63], P = 0.003). Use of continuous infusion was 38%
for the rescue group compared with 19% for controls
(P = 0.104). All other patient and treatment factors
were not significantly different between the rescues and
controls (Appendix S1). An HLR analysis included
ASA and continuous infusion as independent variables
in the first block and adjuvant nonopioids in the second.
The addition of the nonopioid factor significantly
improved the model fit (r2 change = 0.158) and was
associated with an 86% reduced odds of need for rescue
(Table 3). The prognostic ability of this model to detect
the outcome was supported by the c-statistic.
Aim 2: Early clinical predictors of opioid-ADEs and
need for rescue
There were no differences between groups in documented
HR or RR during the PACU stay or in the first 8 h post-
operatively (P > 0.169) (Appendix S2). Table 4 presents a
description of pain and UMSS scores, SpO2 and supple-
mental O2 requirements between children with and with-
out opioid-ADEs. The opioid-ADE group was nearly four
times as likely to have required O2 at PACU DC, and
more than 10 times as likely to have needed it preevent.
Children in the rescue group had a significantly lower
SpO2 in the 12 h prior to the event compared with the
threshold group (86.56 ± 8.2 vs. 93.67 ± 3.91; P = 0.008),
and compared with all others, were more likely to have
needed O2 at PACU DC (OR 5.5 [1.7, 17.82]; P = 0.002)
and preevent (27.86 [7.04, 110.28] P < 0.001). The need
for O2 was not significantly different between threshold
and rescue groups (22% vs. 50%, P = 0.228 at PACU
DC and 44% vs. 81%, P = 0.087 preevent).
Discussion
Findings supported the hypotheses that early use of
adjuvant nonopioids was associated with a lower proba-
bility of opioid-ADE and need for rescue in this setting.
Furthermore, lower SpO2, higher sedation scores, and
use of supplemental O2 at PACU DC and in the early
postoperative period were early signs of later deteriora-
tion, suggesting the need for vigilance and, perhaps,
lowering opioid doses in the presence of these signs.
The mitigating effect of adjuvant nonopioids in this
study is particularly noteworthy. Recent reviews and
studies in adult settings suggest that addition of non-
opioids reduces narcotic consumption, enhances anal-
gesia, and lessens side effects such as nausea and
vomiting (17–20). However, the attenuating effects of
nonopioids for respiratory depression or sedation
have not been well documented, with some studies
suggesting no substantial reduction (21,22) and others
showing reduced sedation but not respiratory depres-
sion (23). Limited data have yielded similar findings
for children, supporting the opioid-sparing and anal-
gesic effects of nonopioids, but lacking support for
serious event mitigation (24). Conflicting findings
between reports may be due, in part, to variations in
methods used to detect and define serious opioid-
ADEs (23). Despite such variations, ASA practice
guidelines state that ‘whenever possible, anesthesiolo-
gists should employ multimodal pain management
therapy’ (25). Given the strong association of this fac-
tor with a lower odds of events and need for rescue,
broader implementation may be warranted. No
© 2012 Blackwell Publishing Ltd
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attempt was made to stratify by type of nonopioid in
this study, and most commonly acetaminophen (10–
15 mgkg1) was administered. A previous review of
adult studies suggested no clear differences in opioid-
or ADE-sparing effects between NSAIDs, paraceta-
mol, and cyclo-oxygenase 2 inhibitors (17); however,
the choice should be made in consideration of the
risk/benefit profiles of these and other adjuvants (26).
Table 1 Characteristics and description of treatment(s) between groups
Opioid-ADE cases N = 25 Controls N = 98 P values OR [95% CI]
Age (mean years ± SD) 8.08 [5.4, 10.7] 6.23 [5.0, 7.5] 0.184 NA
Weight (mean kg ± SD) 28.66 [20.3, 37.02] 26.08 [21.4, 30.7] 0.611 NA
Gender-male n (%) 14 (56) 53 (54) 0.863 0.93 [0.38, 2.24]
Caucasian race n (%) 19 (76) 78 (80) 0.963 0.97 [0.32, 2.93]
Hispanic n (%) 0 4 (4) 1.00 0.96 [0.92, 1.00]
ASA 1 n (%) 0 22 (22) 0.007 0.78 [0.70, 0.86]
ASA 2 n (%) 12 (48) 43 (44) 0.711 1.18 [0.49, 2.85]
ASA 3 n (%) 13 (52) 32 (33) 0.073 2.23 [0.92, 5.45]
ASA 4 n (%) 0 1 (1) 1.000 0.97 [0.97, 1.01]
Emergent case 1 (4%) 9 (9%) 0.685 0.41 [0.05, 3.41]
Comorbid conditions n (%)
Respiratory 9 (36) 22 (22) 0.164 1.94 [0.76, 4.98]
Cardiovascular 4 (16) 13 (13) 0.748 1.25 [0.37, 4.21]
Obstructive sleep apnea 6 (24) 15 (15) 0.302 1.75 [0.60, 5.09]
Neurologic 13 (52) 38 (39) 0.231 1.71 [0.71, 4.14]
Obesity 2 (8) 5 (5) 0.629 1.62 [0.30, 8.87]
Hepato-renal 2 (8) 10 (10) 1.00 0.77 [0.16, 3.74]
Musculoskeletal 13 (52) 21 (21) 0.002 3.97 [1.58, 9.98]
Genito-urinary 3 (12) 3 (3) 0.098 4.32 [0.82, 22.85]
Gastrointestinal 8 (32) 26 (27) 0.585 1.30 [0.50, 3.38]
Surgical severity code (14) n (%)
A –Minimally invasive 5 (20) 30 (31) 0.333 0.57 [0.19, 1.65]
B –Moderately invasive 11 (44) 47 (48) 0.723 0.85 [0.35, 2.06]
C – Significantly invasive 9 (36) 21 (21) 0.130 2.06 [0.80, 5.33]
Perioperative opioids a mean [95% CI]
Intraoperative opioid mgkg1h1 0.087 [0.06, 0.12] 0.079 [0.07, 0.09] 0.535 NA
PACU morphine mgkg1 0.098 [0.06, 0.26] 0.076 [0.003, 0.15] 0.800 NA
Post-PACU IV morphine mgkg1b
0–8 h postoperative 0.095 [0.04, 0.15] 0.072 [0.05, 0.09] 0.253 NA
8–16 h postoperative 0.10 [0.02, 0.19] 0.06 [0.04, 0.08] 0.407 NA
16–24 h postoperative 0.09 [0.004, 0.19] 0.06 [0.04, 0.07] 0.531 NA
24–48 h postoperative 0.26 [0.04, 0.56] 0.12 [0.08, 0.17] 0.421 NA
Postoperative analgesic method n (%); ordered dose morphine equivalentkg1 [CI]
Oral opioid 2 (8); 0.02 [0.00, 0.07] 20 (20); 0.05 [0.04, 0.06] 0.241
0.032
0.34 [0.07, 1.56]
IV prn 9 (36); 0.06 [0.04, 0.08] 25 (26); 0.07 [0.06, 0.07] 0.295
0.293
1.64 [0.65, 4.18]
IV PCA 4 (16); 0.019 [0.015, 0.024] 11 (11); 0.016 [0.015, 0.018] 0.504
0.291
1.51 [0.44, 5.20]
IV NCA 6 (24); 0.02 [0.015, 0.025] 8 (8); 0.018 [0.014, 0.02] 0.026
0.606
3.55 [1.10, 11.43]
Epidural 4 (16); 0.21 [0.17, 0.24] 7 (7); 0.20 [0.14, 0.26] 0.232
0.705
2.48 [0.66, 9.24]
Continuous opioid infusion n (%) 11 (44); 0.01 [0.007, 0.01] 19 (19); 0.010 [0.008, 0.01] 0.011
0.176
3.27 [1.28, 8.32]
Benzodiazepines n (%) 8 (32) 16 (16) 0.078 2.41 [0.89, 6.53]
Adjuvant nonopioid n (%) 11 (44) 77 (79) 0.001 0.21 [0.09, 0.54]
PACU, postanesthesia care unit; IV, intravenous; PCA, patient-controlled analgesia; NCA, nurse-controlled analgesia.
aOpioids represent morphine equivalents (from all routes) based on common equi-analgesic calculations.
bMorphine equivalents by 8 h increments, postoperative day 1 and overall on day 2; there were no significant changes over time between or
within groups (P > 0.10 all comparisons).
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A recent meta-analysis found insufficient dosing of
NSAIDs in most studies in children, suggesting that
better dosing practices may further improve opioid-
sparing and ADE reduction effects (24). Although
nonopioid use was not associated with a lower dose of
opioid in our study, the study was likely underpow-
ered to detect an opioid-sparing effect.
Difficulties predicting which patients are at greatest
risk of opioid-ADE emphasize the importance of careful
surveillance and early detection of deterioration. While,
not surprisingly, high sedation scores and lower SpO2
preceded threshold and rescue events, an important find-
ing was the strength of the relationship between opioid-
ADEs and supplemental O2 use both at PACU DC and
early postoperatively. The trend toward lower SpO2 dur-
ing the PACU stay may have been masked by the use of
supplemental O2, because its use was higher but SpO2
similar by the time of DC. The ability of low-flow O2 to
conceal respiratory depression (RD) is well documented
(27), with evidence of delays from the earliest signs (i.e.,
bradypnea or depressed end-tidal carbon dioxide) to the
onset of hypoxemia (28,29) and impaired recognition in
its presence (30). The wide range of time to recognition of
events in this setting may reflect such delayed recognition.
Of note, the frequency of nursing assessments was higher
for children with opioid-ADEs suggesting an increased
vigilance that may have prevented further deterioration
in this setting. These findings suggest the need for a tiered
approach to managing early signs of deterioration,
starting with decreasing the opioid dose and enhanced
vigilance, and a more restrictive or judicious use of
supplemental O2. The APSF further suggests the use of
capnography when supplemental O2 is in use (9).
The potential for selection bias in this study cannot be
dismissed, despite attempts to minimize this by review-
ing all records across samples and by randomly selecting
controls from procedure sub-groups. The potential for
misclassification of opioid-ADEs was reduced by using
a trigger tool similar to those that improved the reliabil-
ity of ADE identification in other studies (31) and by
independent review by three investigators. Misclassifica-
tion of comorbid conditions, such as OSA, was possible
Table 2 Patient and treatment predictors of opioid-ADE
B (SE) Wald Significance OR [95% CI]
Block 1 Patient factors (Nagelkerke r2 = 0.151; Hosmer-Lemeshow [HL] 0.358; P = 0.002)
ASA-PS 0.67 (0.35) 3.61 0.057 1.95 [0.98, 3.9]
Musculoskeletal 1.21 (0.48) 6.32 0.012 3.36 [1.31, 8.67]
Block 2 Opioid factors (r2 = 0.198; HL = 0.619; P = 0.246)
ASA-PS 0.84 (0.40) 4.53 0.033 2.32 [1.07, 5.04]
Musculoskeletal 0.58 (0.58) 1.00 0.316 1.79 [0.57, 5.60]
IV-NCA 0.43 (0.71) 0.38 0.540 1.54 [0.39, 6.15]
Continuous infusion 0.94 (0.64) 2.17 0.141 2.56 [0.73, 8.91]
Benzodiazepine 0.40 (0.58) 0.49 0.483 1.50 [0.48, 4.63]
Block 3 Nonopioid Factor (r2 = 0.325; HL = 0.741; P = 0.001)
ASA-PS 0.94 (0.44) 4.66 0.031 2.56 [1.09, 6.03]
Musculoskeletal 0.46 (0.61) 0.57 0.452 1.58 [0.48, 5.17]
IV-NCA 0.69 (0.73) 0.90 0.343 2.00 [0.48, 8.34]
Continuous infusion 0.95 (0.68) 1.97 0.160 2.58 [0.69, 9.70]
Benzodiazepine 0.91 (0.62) 2.15 0.143 2.48 [0.74, 8.36]
Adjuvant nonopioid −1.83 (0.55) 10.98 0.001 0.16 [0.05, 0.47]
Posthoc c-statistic = 0.825, standard error = 0.040 [95% CI, 0.747, 0.903]; P < 0.001 (calculated using the predicted probabilities as the test
variable in a receiver operating characteristic curve).
Table 3 Patient and treatment predictors of need for rescue
B (SE) Wald Significance OR [95% CI]
Block 1 (Nagelkerke r2 = 0.093; Hosmer-Lemeshow [HL] 0.220; P = 0.049)
ASA-PS 0.754 (0.41) 3.36 0.067 2.13 [0.95, 4.76]
Continuous infusion 1.15 (0.61) 3.60 0.058 3.16 [0.96, 10.40]
Block 2 (r2 = 0.251; HL = 0.43; P = 0.001)
ASA-PS 0.89 (0.46) 3.78 0.052 2.44 [0.99, 5.99]
Continuous infusion 1.42 (0.68) 4.37 0.037 1.09 [1.09, 15.69]
Adjuvant nonopioid −1.97 (0.61) 10.24 0.001 0.14 [0.04, 0.47]
Posthoc c-statistic = 0.82 [0.735, 0.905]; P < 0.001 (calculated using the predicted probabilities as the test variable in a receiver operating
characteristic curve).
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because these were based on the documented history
and physical exams. To minimize reporting error, com-
orbidities were coded from preoperative anesthesia and
surgery records, as well as hospital admission notes.
Given the small number of adverse events, it is possible
that the model coefficients were overestimated. How-
ever, the goodness of fit and c-statistic showed excellent
model performance. The finding that opioid consump-
tion did not differ between groups must be cautiously
interpreted. Morphine equivalents were calculated using
standard equianalgesic conversions, yet may introduce
confounding given differences in pharmacokinetics and
active metabolites between agents. Furthermore, the ret-
rospective nature of this study precluded the ability to
compare dosage differences over time between groups
given the variable time to events, dosage changes in
response to events (event group) and over time (in con-
trol group). Prospective study controlling for agent and
time is warranted to better examine the impact of opioid
consumption. Lastly, the small samples of children with
rescue and threshold events were likely underpowered to
detect significant differences, and lastly, the likely con-
tribution of other confounders that were overlooked
cannot be dismissed. Further study in larger samples is
warranted to further improve risk stratification.
In summary, findings suggest that early administration
of adjuvant nonopioids may reduce the risk of serious
opioid-ADEs in hospitalized children postoperatively.
Enhanced vigilance and attention to early clinical signs of
deterioration, including the child’s need for supplemental
O2, may facilitate early and effective intervention that
prevents failure to rescue from opioid-ADEs. These find-
ings lend support for recent calls to implement opioid risk
mitigation strategies for hospitalized patients (32).
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Table 4 Early clinical signs and symptoms between groups (data presented as mean [95% confidence interval])
Preoperatively PACU PACU DC POD 1a
Low SpO2
Opioid-ADE 97.7 [96.6, 98.9] 91.6 [87.2, 95.9] 96.0 [94.1, 97.8] 88.6 [85.4, 91.8]
Control 97.7 [96.3, 99.2] 95.0 [93.9, 96.2] 97.5 [97.1, 97.9] 95.7 [95.2, 96.2]
P value 0.284 0.099 0.101 < 0.001
High UMSSb
Opioid-ADE NA 2.4 [1.9, 2.8] 1.3 [1.0, 1.6] 1.9 [1.6, 2.2]
Control NA 2.5 [2.3, 2.7] 1.1 [0.9, 1.3] 1.3 [1.1, 1.5]
P value 0.486 0.267 0.002
Highest Pain Scorec
Opioid-ADE NA 1.8 [0.5, 3.1] 0.28 [0, 0.8] 4.1 [2.9, 5.3]
Control NA 2.9 [2.3, 3.6] 0.79 [0.4, 1.2] 3.7 [3.2, 4.3]
P value 0.117 0.130 0.678
Supplemental O2 use n (%); FiO2
Opioid-ADE RA 19 (83); 0.44 [0.31, 0.57] 9 (39); 0.27 [0.21, 0.34] 17 (68); 0.35 [0.26, 0.47]
Control RA 68 (72); 0.39 [0.33, 0.44] 14 (15); 0.23 [0.21, 0.25] 10 (11); 0.22 [0.21, 0.23]
Odds ratio [95% CI]; P value 1.89 [0.59, 6.06]; 0.408 3.72 [1.35, 10.23]; 0.007 10.82 [3.88, 30.19]; <0.001
PACU, post-anesthesia care unit; DC, discharge; POD, postoperative day; ADE, adverse drug event; O2, oxygen, FiO2, fraction of inspired
oxygen; SpO2, oxygen saturation.
aValues for Opioid-ADE group reflect only those prior to event.
bUMSS = University of Michigan Sedation Scale (0 = awake, alert, 1 = sleepy, but awake, 2 = arouses to voice or light tactile stimuli,
3 = arouses to deep physical stimuli, 4 = unarousable) (13).
cHighest documented pain score (i.e., 0–10, where 0 = no pain, 10 = worst pain).
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